ALKS 5461

After a strong 2017, biotech stocks are on track to end the year in the red despite a record 59 new molecular entity approvals, some noteworthy M&A deals and several breakthrough developments in drug discovery and research. Will the new year mark a reversal in fortunes for these firms? Here...

Shares of Alkermes Plc (NASDAQ: ALKS) lost more than 20 percent early Monday morning after the U.S. Food and Drug Administration said it won't review the company's therapy ALKS-5461. What Happened Alkermes, which mostly focuses on treatments for central nervous system diseases, said...